P.B. Ottevanger

729 total citations
20 papers, 280 citations indexed

About

P.B. Ottevanger is a scholar working on Oncology, Reproductive Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, P.B. Ottevanger has authored 20 papers receiving a total of 280 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 6 papers in Reproductive Medicine and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in P.B. Ottevanger's work include Ovarian cancer diagnosis and treatment (6 papers), Endometrial and Cervical Cancer Treatments (5 papers) and BRCA gene mutations in cancer (2 papers). P.B. Ottevanger is often cited by papers focused on Ovarian cancer diagnosis and treatment (6 papers), Endometrial and Cervical Cancer Treatments (5 papers) and BRCA gene mutations in cancer (2 papers). P.B. Ottevanger collaborates with scholars based in Netherlands, United Kingdom and Belgium. P.B. Ottevanger's co-authors include Nicholas S. Reed, Leen Verleye, Ignace Vergote, Ingrid M.E. Desar, Charlotte Benson, Winette T.A. van der Graaf, P.H.M. de Mulder, Ingrid Boere, Thera P. Links and J. Zwaveling and has published in prestigious journals such as The Lancet Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

P.B. Ottevanger

18 papers receiving 274 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P.B. Ottevanger Netherlands 9 89 74 50 48 46 20 280
Ole‐Erik Iversen Norway 11 54 0.6× 113 1.5× 68 1.4× 61 1.3× 80 1.7× 26 346
Kemal Beksaç Türkiye 10 47 0.5× 20 0.3× 65 1.3× 52 1.1× 37 0.8× 37 279
Giusi Santangelo Italy 11 129 1.4× 90 1.2× 119 2.4× 28 0.6× 17 0.4× 37 369
Christianne Lok Netherlands 12 72 0.8× 34 0.5× 104 2.1× 15 0.3× 188 4.1× 23 375
Michelle D. Sakala United States 10 112 1.3× 117 1.6× 90 1.8× 23 0.5× 26 0.6× 22 305
Janelle M. Fauci United States 9 45 0.5× 56 0.8× 204 4.1× 34 0.7× 54 1.2× 19 366
Silverberg Sg United States 9 70 0.8× 85 1.1× 75 1.5× 52 1.1× 34 0.7× 14 293
Eirwen M. Miller United States 8 63 0.7× 44 0.6× 46 0.9× 29 0.6× 14 0.3× 33 189
Cheng-I Liao Taiwan 10 157 1.8× 109 1.5× 120 2.4× 35 0.7× 13 0.3× 45 493
Tolga Taşçı Türkiye 15 258 2.9× 339 4.6× 62 1.2× 36 0.8× 107 2.3× 55 478

Countries citing papers authored by P.B. Ottevanger

Since Specialization
Citations

This map shows the geographic impact of P.B. Ottevanger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P.B. Ottevanger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P.B. Ottevanger more than expected).

Fields of papers citing papers by P.B. Ottevanger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P.B. Ottevanger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P.B. Ottevanger. The network helps show where P.B. Ottevanger may publish in the future.

Co-authorship network of co-authors of P.B. Ottevanger

This figure shows the co-authorship network connecting the top 25 collaborators of P.B. Ottevanger. A scholar is included among the top collaborators of P.B. Ottevanger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P.B. Ottevanger. P.B. Ottevanger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Westgeest, Hans M., Ingrid Boere, P.B. Ottevanger, et al.. (2023). The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis. Gynecologic Oncology. 171. 83–94. 44 indexed citations
3.
4.
Boer, Stephanie M. de, Melanie Powell, Linda Mileshkin, et al.. (2019). Patterns of Recurrence and Survival in the Randomized Portec-3 Trial of Chemoradiotherapy for High-Risk Endometrial Cancer. International Journal of Radiation Oncology*Biology*Physics. 105(1). S1–S2.
5.
Kapiteijn, Ellen, P.B. Ottevanger, Thera P. Links, et al.. (2019). Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data. European Journal of Endocrinology. 182(2). 131–138. 44 indexed citations
6.
Timmermans, Maite, Gabe S. Sonke, Koen Van de Vijver, et al.. (2019). Localization of distant metastases defines prognosis and treatment efficacy in patients with FIGO stage IV ovarian cancer. International Journal of Gynecological Cancer. 29(2). 392–397. 7 indexed citations
7.
Desar, Ingrid M.E., P.B. Ottevanger, Charlotte Benson, & Winette T.A. van der Graaf. (2017). Systemic treatment in adult uterine sarcomas. Critical Reviews in Oncology/Hematology. 122. 10–20. 40 indexed citations
8.
Westermann, Anneke M., et al.. (2016). An impressive response to pazopanib in a patient with metastatic endometrial carcinoma.. PubMed. 74(9). 410–413. 9 indexed citations
9.
Ottevanger, P.B., S.A.M. van de Schans, Helena M. Dekker, et al.. (2015). Trends in quality of non-Hodgkin’s lymphoma care: is it getting better?. Annals of Hematology. 94(7). 1195–1203. 2 indexed citations
10.
Fluit, Cornelia, et al.. (2013). Teaching adjuvant endocrine breast cancer treatment to medical students.. PubMed. 71(4). 215–9. 1 indexed citations
11.
Amant, Frédéric, Kristel Van Calsteren, Lieven Lagae, et al.. (2012). Observational study on the long term cognitive and cardiac outcome after prenatal exposure to chemotherâpy in children 18 months or older. The Lancet Oncology. 13(3). 2 indexed citations
12.
13.
Thomas, Chris M.G., Fred C.G.J. Sweep, René H.M. Verheijen, et al.. (2012). Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia. European Journal of Cancer. 49(4). 860–867. 20 indexed citations
14.
Amant, Frédéric, Kristel Van Calsteren, M Halaška, et al.. (2011). Cognitive and Cardiac Outcome After Prenatal Exposure to Chemotherapy in Children 18 Months or Older. European Journal of Cancer. 47. 8–8. 1 indexed citations
15.
Verleye, Leen, Ignace Vergote, Nicholas S. Reed, & P.B. Ottevanger. (2009). Quality assurance for radical hysterectomy for cervical cancer: the view of the European Organization for Research and Treatment of Cancer—Gynecological Cancer Group (EORTC-GCG). Annals of Oncology. 20(10). 1631–1638. 50 indexed citations
16.
Hermens, Rosella, Volker Runde, Hub Wollersheim, et al.. (2008). Possibilities for transborder cooperation in breast cancer care in Europe: A comparative analysis regarding the content, quality and evidence use of breast cancer guidelines. The Breast. 17(5). 464–471. 8 indexed citations
17.
Ottevanger, P.B. & P.H.M. de Mulder. (2005). The quality of chemotherapy and its quality assurance. European Journal of Surgical Oncology. 31(6). 656–666. 11 indexed citations
18.
Ottevanger, P.B., et al.. (2003). Quality assurance in clinical trials. Critical Reviews in Oncology/Hematology. 47(3). 213–235. 26 indexed citations
19.
Ottevanger, P.B., L.V.A.M. Beex, R.P.T.M. Grol, & P.H.M. de Mulder. (1999). Quality of chemotherapy for malignant epithelial ovarian carcinoma in a non trial setting.. European Journal of Cancer. 35. 1 indexed citations
20.
Ottevanger, P.B., L.V.A.M. Beex, R.P.T.M. Grol, & PHM de Mulder. (1999). Adherence to a regional guideline for treatment of malignant epithelial ovarian carcinoma. European Journal of Cancer. 35. S238–S239. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ole‐Erik Iversen Breakdown of academic impact, for papers by Kemal Beksaç Breakdown of academic impact, for papers by Giusi Santangelo Breakdown of academic impact, for papers by Christianne Lok Breakdown of academic impact, for papers by Michelle D. Sakala Breakdown of academic impact, for papers by Janelle M. Fauci Breakdown of academic impact, for papers by Silverberg Sg Breakdown of academic impact, for papers by Eirwen M. Miller Breakdown of academic impact, for papers by Cheng-I Liao Breakdown of academic impact, for papers by Tolga Taşçı
Rankless by CCL
2026